Leupin, Nicolas

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 9.

Journal Article

Bianchi, Matteo; Reichen, Christian; Croset, Amelie; Fischer, Stefanie; Eggenschwiler, Aline; Grübler, Yvonne; Marpakwar, Rajlakshmi; Looser, Thamar; Spitzli, Patricia; Herzog, Christel; Villemagne, Denis; Schiegg, Dieter; Abduli, Liridon; Iss, Chloé; Neculcea, Alexandra; Franchini, Marco; Lekishvili, Tamara; Ragusa, Simone; Zitt, Christof; Kaufmann, Yvonne; ... (2024). The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. Cancer immunology research, 12(7), pp. 921-943. American Association for Cancer Research 10.1158/2326-6066.CIR-23-0692

Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Ulrike; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Francisco, David; Bruggmann, Remy; van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; de Haard, Hans; Leupin, Nicolas; ... (2020). Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nature medicine, 26(9), pp. 1459-1467. Springer Nature 10.1038/s41591-020-0910-8

Leupin, Nicolas; Schuller, Jan C; Solenthaler, Max; Heim, Dominik; Rovo, Alicia; Beretta, Kurt; Gregor, Michael; Bargetzi, Mario J; Brauchli, Peter; Himmelmann, Andreas; Hanselmann, Silvia; Zenhäusern, Reinhard (2010). Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leukemia & lymphoma, 51(4), pp. 613-9. London: Informa Healthcare 10.3109/10428191003624231

Buonomano, Roberto; Brinkmann, Franziska; Leupin, Nicolas; Boscacci, R; Zimmermann, Arthur; Muller, Norbert; Fux, Christoph (2009). Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis. Scandinavian journal of infectious diseases, 41(10), pp. 777-81. Oslo: Informa Healthcare 10.1080/00365540903104127

Schuller, Jan C.; Mayer, Michael; Lanz, Doris; Hsu Schmitz, Shu-Fang; Brauchli, Peter; Leupin, Nicolas (2009). A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemporary clinical trials, 30(3), pp. 201-204. New York, N.Y.: Elsevier 10.1016/j.cct.2009.01.010

Vetsch, Gabi; Baumann, Christa K; Kläy, Marco; Leupin, Nicolas; Rentsch, Cyrill; Mueller-Garamvölgyi, Esther; Bürgi, Ulrich; Schiemann, Uwe (2008). [Malignant lymphoma of the prostate--diagnosis on the second biopsy]. Medizinische Klinik, 103(4), pp. 245-8. München: Urban & Vogel 10.1007/s00063-008-1034-y

Rizzi, Mattia; Tschan, Mario P; Britschgi, Christian; Britschgi, Adrian; Hügli, Barbara; Grob, Tobias J; Leupin, Nicolas; Mueller, Beatrice U; Simon, Hans-Uwe; Ziemiecki, Andrew; Torbett, Bruce E; Fey, Martin F; Tobler, Andreas (2007). The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. Journal of leukocyte biology, 81(6), pp. 1599-608. Bethesda, Md.: Society for Leukocyte Biology 10.1189/jlb.0606400

Leupin, Nicolas; Kuhn, Alexandre; Hügli, Barbara; Grob, Tobias J; Jaggi, Rolf; Tobler, Andreas; Delorenzi, Mauro; Fey, Martin F (2006). Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. British journal of haematology, 135(4), pp. 520-3. Oxford: Wiley-Blackwell 10.1111/j.1365-2141.2006.06342.x

Conference or Workshop Item

Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Vera; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Ferreira, David; Bruggmann, Remy; Van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; De Haard, Hans; Leupin, Nicolas; ... (2 December 2018). 2680 Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial (Unpublished). In: ASCO 2018. 2. Dezember 2018.

This list was generated on Sat Dec 21 17:22:37 2024 CET.
Provide Feedback